Background-An attempt was made to improve metachronous oesophageal cancer prognosis through bi-annual systematic esophageal endoscopy screening in patients treated for head and neck cancer.
Introduction
The phenomenon of multiple upper aerodigestive tract cancers was described as early as 100 years ago by Billroth and Von Winiwarter [1] . The field cancerization hypothesis suggests that the entire upper aerodigestive tract undergoes mutations by exogenous carcinogenic factors such as tobacco and alcohol, and is prone to multifocal cancers [2] .
Second primary tumors in head and neck patients occur primarily in the upper aerodigestive tract, constituting a major threat to the survival of these patients. Moreover, as the survival rate of patients with upper aerodigestive tract cancers has increased, the detection of a second cancer has also increased. The constant annual risk of treated head and neck cancer patients developing a second primary tumor ranges from 1.5% to 5% [3] [4] [5] , On average, one fourth of all patients treated for head and neck carcinoma will suffer from metachronous cancer in the same field [6] [7] [8] [9] .
In a retrospective cohort analysis of the Epidemiology
Program of the US National Cancer Institute, the relative risk of developing a metachronous esophageal squamouscell carcinoma following head and neck cancer was 9.5 in men and 38.8 in women [10] . As early diagnosis of esophagus cancer has a major impact on prognosis, we therefore tried to improve metachronous esophageal cancer prognosis through bi-annual systematic esophageal endoscopy screening in patients treated for head and neck cancer.
Patients and methods
From 1987 to 1997, 1560 patienb were treated for primary head and neck squamous-cell carcinoma (HNSCC) in our institution. The median age of these patients was 60 years (range 29-85 years). had multiple synchronous HNSCC. Tumors were considered to be second synchronous primaries when the subsequent tumor was located at a site distant from the margin of excision of the first primary tumor, separated by normal mucosa and discovered within the first 6 months of initial tumor diagnosis. During this 10 year follow-up period, the numbers of patients with quadruple, triple, and double metachronous HNSCC sites were respectively 10, 35, and 123. A bi-annual systematic esophageal endoscopy screening, beginning six months after treatment of the primary tumors, was proposed to all these patients. All esophageal endoscopies were performed with flexible scopes under local anaesthesia by the same gastro-enterologist. No staining procedure was used during these endoscopies. During this 10 year-follow-up period, 1560 patients underwent a total number of 9682 esophageal endoscopies.
Results

Fifty-four metachronous tumors
Out of these 1560 patients, systematic endoscopy revealed 50 esophageal carcinomas, 2 gastric adenocarcinomas, 1 gastric lymphoma, and 1 gastric metastasis of squamous-cell carcinoma. The compliance to this systematic procedure was excellent, without any major complications.
Fifty esophageal carcinomas
According to the initial HNSCC anatomic site, 2.6% of patients with oral cavity tumor, 5.7% of patients with oropharynx tumor, 2.3% of patients with hypopharynx tumor, and 1.7% of patients with larynx tumor, had a metachronous esophageal carcinoma. The median age of patients with metachronous esophageal carcinomas was 59 years (range 37-84 years). The median time lapse from the first HNSCC was 47 months (range 7-168 months) ( Table 1 ). In addition to these 50 esophageal tumors, another 22 tumors were diagnosed during the follow-up of these 50 patients (10 HNSCC, 9 non-smallcell lung cancer (NSCLC), 1 bladder cancer, 1 anal cancer, 1 hepatocarcinoma).
All these esophageal tumors were squamous-cell cancers (SCC), and 86% were invasive (43 of 50). The tumor localization was as follows: upper third 35%, middle third 52%, lower third 13%. Five tumors were bifocal. The histologic grade distribution was 33% well differentiated, 25% moderately differentiated, and 42% poorly differentiated tumors. Due to after-effects from previous HNSCC treatment, it was impossible to use echo-endoscopy to find the TNM value and we therefore evaluated the tumor size based on the fraction of esophageal circumference covered by the tumor. Eight per cent of the tumors covered the whole circumference, 2% of the tumors covered more than half of it, 26% of the tumors covered between a half and a quarter of it, and 64% covered less than a quarter of the circumference. Locoregional status of lymph nodes was determined by CT scan in 37 patients, and 16% had nodal involvement. Four patients had metastases when esophageal tumor was diagnosed. The esophageal carcinoma treatments were as indicated in Table 2 . Among the 7 in situ tumors, 2 disappeared with an anti-acid medication, 3 became invasive with a delay of transformation of 8, 13 and 28 months, and 2 patients died of non-malignant causes while having in situ esophageal tumors. Five patients had surgical treatment and one patient is still alive with a seven-year follow-up. Thirty-one patients were treated with an association of chemotherapy and radiation, and their median survival was twelve months (range 1-78 months) Two of these patients show complete remission with a follow-up of, respectively, 52 and 78 months.
The causes of death are reported in Table 3 . Causes related to the esophageal tumor, with esophageal progression, metastasis evolution, or treatment toxicity, were responsible for 41.1% of the deaths, all metastasis being arbitrarily related to esophageal tumor evolution. Non malignant causes were responsible for 28.9% of deaths. Cancers that were not of esophageal origin, were responsible for 26.6% of deaths.
The median survival of the 50 patients after the initial HNSCC diagnosis was 70.5 months. The median survival after the esophageal tumor diagnosis was 16 months (range 1-120 months) ( Figure 1 ). Three patients with initial invasive tumor are presently alive and in complete remission, with one patient having been treated through surgery and two patients treated through the combination of chemotherapy-radiotherapy. Their follow-ups are, respectively, 52, 78, and 84 months.
Discussion
In the present study, over a 10-year period, systematic bi-annual esophageal endoscopy uncovered metachronous esophageal tumors in 3.2% of 1560 patients originally treated for head and neck carcinoma, developing in a median time of 47 months. Patients with initial oropharyngeal tumors had a significantly higher risk of metachronous esophageal SCC, compared to the other tumor sites {P < 0.02 with Fisher exact test). The median survival of the 50 patients was 70.5 months after the primary HNSCC diagnosis, and 16 months after the esophageal SCC diagnosis. We should note here that optimal treatment for these patients often required adaptation, due to the previous HNSCC treatment. For example, 47% of the upper third esophageal were located in the supraclavicular radiation zone of the initial HNSCC.
Large prospective panendoscopy series with routine inspections of the pharynx, larynx, esophagus, and tracheobronchial tree in patients undergoing initial evaluation of head and neck cancer found a 1.8%-8% incidence of synchronous esophagus cancer [11, 12] . There have been few studies which have focused on metachronous esophagus cancer. There were no cases of metachronous esophageal tumors in the retrospective serie of the Regina Elena Cancer Institute, with a median follow-up of 3.2 years [4] . Kinzie JJ et al. reported that 0.93% (3 of 321) of their HNSCC patients developed a metachronous esophageal cancer over a two-year period [13] . This incidence was 1% (2 of 200) over a four-year period for Shaha et al. [14] . Among 1294 patients with primary HNSCC cancer diagnosed at the Memorial Sloan-Kettering Cancer Center between 1970 and 1979, 21 patients (1.6%) developed a metachronous esophageal tumor [15] . Over a period of time similar to that of our study, this investigation uncovered fewer metachronous esophageal tumors (1.6% compared to 3.2%). We assume that this observation might be secondary to different epidemiologic risk factors, with more alcoholic abuse in the French study, and more tobacco abuse in the American study. In the Memorial Sloan-Kettering Cancer Center study, the median time lapse between the appearance of the primary tumor and the metachronous lung or esophageal tumor was 43 months, and the median survival after diagnosis of the metachronous lung and esophageal tumor was seven months. Abrasive esophageal cytology was evaluated for HNSCC metachronous cancer screening [16] . Twenty premalignant or early malignant lesions of the esophagus were revealed in three hundred twenty patients during a mean follow-up of four years.
The risk for surviving patients of developing a metachronous tumor does not seem to decrease with time, according to data from the Radiation Therapy Oncology Group and the Connecticut Tumor [6, 17] . This risk is thought to be independent of the stage of the primary tumor, and the prognostic value of the index tumor anatomic site remains controversial [9, 17] . For Licciardello et al., both synchronous and metachronous second cancers occur at higher rates when the index primary tumor is located in the oral cavity [9] . On the contrary, Cooper et al. showed minor differences in frequency for different primary sites [6] . In the present study, metachronous esophageal SCC occurred at significantly higher rate when the initial tumor was located in the oropharynx. It was suggested that patients with the earliest stage of disease have the greatest risk of developing metachronous cancers since patients with more advanced stages of disease have a shorter survival [17] . Of the 50 patients in the present study, 32% of the initial HNSCC localizations were in stage I, 24% in stage II, 36% in stage III, and 8% in stage IV.
There are few studies on the effect of initial HNSCC treatment on second primary tumor risk. Cases of radiation-induced carcinoma of the hypopharynx were reported in the long-term follow-up of patients treated with irradiation for larynx carcinoma [18] , and predisposition toward head and neck cancer was reported in patients exposed to radiation upon treatment for benign disease during childhood [19] . In two different series, no difference in the respective incidence of metachronous tumors was observed in groups of patients treated with radiotherapy or surgery [20, 21] . On the contrary, radiation was demonstrated to reduce the prevalence of second cancer in the same field by Kogelnik et al., presumably by sterilizing dysplasia and microscopic neoplasia [22] . Some studies on second primary carcinomas showed a significantly lower survival rate when metachronous cancers arose within prior irradiated tissue [23, 24] . This might reflect that treatment given to the second tumor was less effective because of previous radiotherapy. All the same, the greatest risk factor for second primary head and neck tumors is certainly continuous abuse of alcohol and tobacco after initial head and neck tumor treatment [25] .
Tachimori et al. have reported a study of 41 patients with initial HNSCC and metachronous esophageal tumors [26] . These metachronous esophageal tumors were not discovered by systematic esophageal endoscopy screening, and the average time interval between HNSCC and esophageal tumor diagnosis was 42 months, ranging from 9 months to 9 years. The two-year survival rate was 27.5% and five-year survival rate was 10% after treatment of the esophageal tumor. In our study, these survival rates were respectively 37% and 14.5%, thanks to consistent systematic endoscopy imposed on all patients. In more than half of the patients, the cause of death was not related to the esophageal tumor or its treatment (28.9% related to non malignant causes and 26.6% related to cancers that were not of esophageal origin). Given the short survival of these patients and the elevated non neoplastic co-morbidity, any potential benefit from this time-consuming procedure of systematic esophageal endoscopy is debatable. Finally, this early detection program might be limited to patients with oropharynx tumors of whom nearly 6% will develop a metachronous esophageal tumor according to our study.
